| Business Summary | | IVAX
Corporation
is
a
multinational
company
engaged
in
the
research,
manufacture
and
marketing
of
pharmaceutical
products.
Ivax
manufactures
and
markets
several
brand
name
pharmaceutical
products
and
a
variety
of
generic
and
over-the-counter
pharmaceutical
products,
primarily
in
the
United
States
and
the
United
Kingdom.
The
Company
also
has
subsidiaries
located
throughout
the
world.
In
addition,
IVAX
holds
approximately
470
United
States
and
foreign
patents
and
has
several
hundred
United
States
and
foreign
patent
applications
pending. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | IVAX
Corp.
is
a
holding
company
with
subsidiaries
engaged
primarily
in
the
R&D,
manufacturing
and
marketing
of
branded
and
generic
pharmaceuticals.
For
the
six
months
ended
6/30/01,
revenues
rose
53%
to
$561.7
million.
Net
income
before
acctg.
change
and
extraordinary
item
totalled
$128
million,
up
from
$59.1
million.
Revenues
reflect
increased
volume
and
new
products
in
the
North
American
region.
Net
income
reflects
a
$10.3
million
gain
on
the
sale
of
a
partial
interest
in
IVAX
Diagnostics. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| Phillip Frost, M.D., 64 Chairman
and CEO | $1.4M | Neil Flanzraich, 57 Vice
Chairman and Pres | 1.1M | Isaac Kaye, 71 Deputy
CEO | 1.2M | Thomas Beier, 55 Sr.
VP- Fin. and CFO | -- | Steven Rubin Sr. VP, Gen. Counsel, Sec. | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|